| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
Poxel S.A. (LSE: 0RA2)
0RA2 Technical Analysis
5
| As on 21st Jan 2025 0RA2 STOCK Price closed @ 0.38 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 0.50 & Strong Sell for SHORT-TERM with Stoploss of 0.49 we also expect STOCK to react on Following IMPORTANT LEVELS. |
0RA2STOCK Price
| Open | 0.38 | Change | Price | % |
| High | 0.66 | 1 Day | 0.14 | 58.33 |
| Low | 0.38 | 1 Week | 0.20 | 111.11 |
| Close | 0.38 | 1 Month | 0.19 | 100.00 |
| Volume | 35000 | 1 Year | -0.20 | -34.48 |
| 52 Week High 0.78 | 52 Week Low 0.13 | ||||
LSE UK Most Active Stocks
| PREM | 0.03 | 0.00% |
| NTOG | 0.04 | 33.33% |
| TRP | 0.03 | 0.00% |
| LLOY | 61.00 | 3.99% |
| CPX | 0.15 | 7.14% |
| SYME | 0.00 | % |
| DKE | 0.15 | 0.00% |
| NNN | 0.09 | 50.00% |
| DMTR | 0.03 | 0.00% |
| BOIL | 0.08 | 0.00% |
LSE UK Top Gainers Stocks
LSE UK Top Losers Stocks
| 0RA2 Daily Charts |
0RA2 Intraday Charts |
Whats New @ Bazaartrend |
0RA2 Free Analysis |
|
|
0RA2 Important Levels Intraday
| RESISTANCE | 0.92 |
| RESISTANCE | 0.75 |
| RESISTANCE | 0.64 |
| RESISTANCE | 0.53 |
| SUPPORT | 0.23 |
| SUPPORT | 0.12 |
| SUPPORT | 0.01 |
| SUPPORT | -0.16 |
0RA2 Forecast January 2025
| 4th UP Forecast | 0.8 |
| 3rd UP Forecast | 0.67 |
| 2nd UP Forecast | 0.58 |
| 1st UP Forecast | 0.5 |
| 1st DOWN Forecast | 0.26 |
| 2nd DOWN Forecast | 0.18 |
| 3rd DOWN Forecast | 0.09 |
| 4th DOWN Forecast | -0.04 |
0RA2 Weekly Forecast
| 4th UP Forecast | 0.44 |
| 3rd UP Forecast | 0.42 |
| 2nd UP Forecast | 0.41 |
| 1st UP Forecast | 0.40 |
| 1st DOWN Forecast | 0.36 |
| 2nd DOWN Forecast | 0.35 |
| 3rd DOWN Forecast | 0.34 |
| 4th DOWN Forecast | 0.32 |
0RA2 Forecast2025
| 4th UP Forecast | 1.9 |
| 3rd UP Forecast | 1.41 |
| 2nd UP Forecast | 1.11 |
| 1st UP Forecast | 0.81 |
| 1st DOWN Forecast | -0.05 |
| 2nd DOWN Forecast | -0.35 |
| 3rd DOWN Forecast | -0.65 |
| 4th DOWN Forecast | -1.14 |
Poxel S.A. ( LSE UK Symbol : 0RA2 )
Sector : N/A And Other Stocks in Same Sector
Sector : N/A And Other Stocks in Same Sector
0RA2 Business Profile
Poxel S.A., a clinical-stage biopharmaceutical company, develops novel treatments for metabolic diseases, type 2 diabetes, and liver diseases. The company's lead product is Imeglimin, an oral drug candidate, which completed Phase III clinical development stage in Japan, as well as in Phase III in the United States and Europe for the treatment of type 2 diabetes that improves pancreatic beta cell function, reduces insulin resistance, and decreases cardiovascular and metabolic disease risk factors, such as heightened blood lipid levels and excess body weight. It also develops PXL770, an adenosine monophosphate-activated protein kinase enzyme, which is in a Phase 2a clinical trial that treats chronic metabolic diseases, including diseases that affect the liver, such as non-alcoholic steatohepatitis (NASH). The company has a licensing agreement with Enyo Pharma S.A.S. for the development of PXL007 (EYP001), a synthetic non-steroidal and non-bile acid FXR agonist that is in Phase II study for the treatment of hepatitis B and NASH; and DeuteRx LLC for the development of PXL065, a mitochondrial pyruvate carrier inhibitor, which is in a phase I clinical trial for the treatment of NASH. Poxel S.A. was incorporated in 2009 and is headquartered in Lyon, France. Address: Immeuble Le Sunway, Lyon, France, 69007
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service